Merck and Nectin to Study Novel Anti-PVR Candidate with Keytruda

Merck and Nectin to Study Novel Anti-PVR Candidate with Keytruda

Source: 
BioSpace
snippet: 

Merck and New Jersey-based Nectin Therapeutics announced a research collaboration agreement Tuesday to study the safety and efficacy of Nectin’s investigational antibody NTX1088 in locally advanced and metastatic solid tumors.